Cardiac Risk Pathways in BAV: Cannabis, Tryptamines, Neuroplastogens

Mechanistic Study Reveals BAV-Specific Cardiac Risks from Psychoactive Compounds

A November 2026 mechanistic analysis published via OpenAlex (W7225144058) details how individuals with bicuspid aortic valve (BAV)—the most common congenital heart valve anomaly—may face distinct cardiac risks when exposed to cannabis, tryptamines (such as psilocybin and DMT), or novel neuroplastogen analogs. The study, anchored to a reconstructed openSNP genotype cohort, proposes that each drug class interacts with BAV pathology through separable molecular pathways, and calls for registry-scale validation and pharmacogenomic risk stratification in psychedelic research and clinical use.

Distinct Mechanisms: Drug Class Interactions with BAV Pathophysiology

Bicuspid aortic valve (BAV) creates a unique substrate for drug-induced cardiac vulnerability, due to its propensity for valvular calcification and aortic aneurysm, governed by transforming growth factor-β (TGF-β) signaling and nitric oxide (NO) homeostasis. The study proposes three mechanistic risk pathways:

• Cannabis: Acts hemodynamically and vasculopathically, potentially exacerbating BAV-related aortic wall weakness and calcification via CB1/CB2 receptor-mediated effects on vascular tone and inflammation.
• Tryptamines (psilocybin, DMT, 5-MeO-DMT): Pose a risk of valvular fibrosis through 5-HT2B receptor activation, a pathway implicated in drug-induced cardiac valvulopathy, with the operative risk variable being cumulative 5-HT2B occupancy rather than affinity alone.
• Neuroplastogen analogs: Designed to avoid 5-HT2B agonism, these compounds may present a lower direct risk to BAV tissue, but the study notes that medicinal chemistry strategies must be rigorously validated in human populations with common cardiovascular variants.

By integrating receptor pharmacology with exposure patterns (macrodose vs. microdose regimens), the analysis highlights that risk is not uniform across or within drug classes, and that cumulative exposure and genetic context are critical factors.

Pharmacogenomics and the openSNP BAV Cohort: A Concrete Substrate for Risk

The study's unique contribution is its anchoring to a reconstructed openSNP genotype cohort (phenotype-361, "Bicuspid aortic valve"), comprising 19 individuals with recoverable genotypes across a 17-SNP panel. Most cohort members carried at least one TGFB1 −509 variant allele and five of eight had a NOS3 −786C allele, both of which are implicated in BAV pathogenesis and vascular reactivity. This finding demonstrates that the substrate for pharmacogenomic interaction is common, not rare, among BAV patients—an insight not widely addressed in prior psychedelic safety literature.

The authors provide an exposure × phenotype risk-stratification matrix and six falsifiable hypotheses for registry-scale validation, explicitly stating that their analysis is hypothesis-generating rather than clinical guidance. This approach is notable for its transparency and for highlighting concrete, testable questions for future research.

Implications for Research, Policy, and Ethics in Psychedelic Trials

This mechanistic risk analysis raises substantive considerations for the design of psychedelic clinical trials and the development of regulatory protocols. The presence of common cardiovascular genetic variants in the general population means that exclusion criteria, informed consent, and safety monitoring protocols may need to be updated to account for BAV-specific vulnerabilities. The study suggests that pharmacogenomic screening could become a standard component of risk stratification in psychedelic research, particularly as registry-scale data become available.

From a policy perspective, the findings may influence regulatory agencies such as the U.S. Food and Drug Administration (FDA) and Health Canada to require more granular cardiovascular risk assessments in trial protocols for psychoactive compounds, especially those with serotonergic or cannabinoid activity. The ethical imperative to protect vulnerable subpopulations—who may not be aware of their BAV status—adds complexity to trial recruitment and patient selection.

Risks, Unknowns, and the Path Forward

While the analysis is rigorous, it is hypothesis-generating and not a substitute for clinical data. The primary risks include the potential for unrecognized cardiac events in BAV patients exposed to these compounds, and the possibility that medicinal chemistry strategies to avoid 5-HT2B agonism may not fully eliminate risk in genetically susceptible individuals. Unknowns remain regarding the dose-response relationship, the impact of chronic vs. acute exposure, and the interaction of multiple pharmacogenomic variants.

Looking forward, the authors call for registry-scale validation of their hypotheses, ideally through prospective data collection in large, diverse cohorts. This would allow for more precise risk quantification and inform the development of evidence-based guidelines for psychedelic use in populations with cardiovascular anomalies.

How we research: This analysis was prepared by Dr. Alex M. Roth, PhD (Biomedical Sciences), with review of the primary OpenAlex source and direct reference to the reconstructed openSNP dataset. Reviewed by Dr. Roth on 2026-11-04.